Sysmex (OTCMKTS:SSMXY) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Sysmex (OTCMKTS:SSMXY) posted its quarterly earnings results on Friday. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.02, Zacks reports. Sysmex had a net margin of 7.13% and a return on equity of 7.23%. Sysmex updated its FY 2026 guidance to 0.382-0.382 EPS.

Sysmex Price Performance

Shares of SSMXY traded up $0.64 during trading hours on Friday, reaching $10.94. 31,586 shares of the company’s stock traded hands, compared to its average volume of 214,699. The stock has a market cap of $6.89 billion, a PE ratio of 28.79 and a beta of 1.05. The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The firm’s 50 day simple moving average is $9.34 and its 200-day simple moving average is $9.06. Sysmex has a 12 month low of $8.01 and a 12 month high of $14.20.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered shares of Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold”.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.